News

Gilead Sciences, Inc. (NASDAQ: GILD) is one of the. The company announced that the US FDA approved Yeztugo ® (lenacapavir), ...
"Analysis shows Yeztugo approval a ‘momentous step’ for HIV prevention" was originally created and published by ...
As Gilead Sciences gets underway with the key launch of its twice-yearly pre-exposure prophylaxis (PrEP) HIV med, the company ...
HIV prevention pills are no different. The good news is PrEP (pre-exposure prophylaxis) is extremely effective and generally ...
Increased PrEP usage is linked to decreased HIV diagnosis rates, with a notable decline from 13.0 to 10.6 per 100,000 over a decade. State-level PrEP coverage significantly impacts HIV diagnosis rates ...
Winning Founding Managing Editor and Executive Director of Cns (Citizen News Service) and Is a Feminist, Health and Development Justice Advocate.
The US Food and Drug Administration has approved Yeztugo (lenacapavir), an injectable HIV-1 capsid inhibitor, as preexposure prophylaxis (PrEP) to reduce the risk for sexually acquired HIV.
Presented by The Coalition to Strengthen America’s Healthcare{beacon} Health Care Health Care   The Big Story SCOTUS upholds ...
The Supreme Court on Friday upheld the constitutionality of an ObamaCare requirement that insurance companies cover certain ...
Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.